BlackRock Advisors’s Aevi Genomic Medicine Inc GNMX Stock Holding History

BlackRock Advisors’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$86K	Buy	16,692 +1,027	+7%	+$5.4K	﹤0.01%	3098
2016 Q3	$87K	Buy	15,665 +4,522	+41%	+$25.8K	﹤0.01%	3079
2016 Q2	$62K	Buy	11,143 +168	+2%	+$882	﹤0.01%	3173
2016 Q1	$48K	Hold	10,975	–	–	﹤0.01%	3176
2015 Q4	$66K	Sell	10,975 -1,752	-14%	-$11.9K	﹤0.01%	3103
2015 Q3	$100K	Buy	12,727 +832	+7%	+$6.45K	﹤0.01%	3107
2015 Q2	$73K	Buy	11,895 +8,070	+211%	+$62.5K	﹤0.01%	3263
2015 Q1	$31K	Hold	3,825	–	–	﹤0.01%	3358
2014 Q4	$19K	Buy	+3,825	New	+$18.9K	﹤0.01%	3523

Other funds holding GNMX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

BlackRock Advisors's GNMX Position: Q4 2016 in Review

BlackRock Advisors increased its Aevi Genomic Medicine Inc (GNMX) stake by 6.6% in Q4 2016, buying an estimated $5.4K and bringing the position to 16,692 shares worth $86K. The position accounts for ﹤0.01% of the portfolio, ranked #3098.

BlackRock Advisors first reported a position in GNMX in Q4 2014 and has held it in 9 quarters since. The position peaked at $100K in Q3 2015. 76 funds tracked by Wall St. Rank hold GNMX as of Q4 2016.

BlackRock Advisors held 16,692 shares of Aevi Genomic Medicine Inc worth $86K as of Q4 2016.
BlackRock Advisors bought 1,027 Aevi Genomic Medicine Inc shares in Q4 2016, an estimated $5.4K.
Aevi Genomic Medicine Inc made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3098 holding.
BlackRock Advisors first reported a position in Aevi Genomic Medicine Inc in Q4 2014 and has held it in 9 quarters since.
BlackRock Advisors's Aevi Genomic Medicine Inc position peaked at $100K in Q3 2015.
76 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.